Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 8/20 | 0.45 |
| ▸ | MAPT | P10636 | 4/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13664214 | 0.89 | MARS1 (0.37) | CNR1MAPTKMT2AMEN1KDM4E | |
| SCHEMBL13664168 | 0.84 | MAPT (0.50) | CNR1MAPTKMT2AMEN1KDM4E | |
| SCHEMBL13664195 | 0.81 | KDM4E (0.50) | CNR1MAPTKMT2AMEN1KDM4E | |
| SCHEMBL13664184 | 0.79 | CNR1 (0.40) | CNR1MAPTKMT2AMEN1KDM4E | |
| SCHEMBL13664200 | 0.79 | MAPT (0.42) | CNR1MAPTKMT2AMEN1KDM4E | |
| SCHEMBL13664198 | 0.77 | GABRP (0.41) | CNR1MAPTKMT2AMEN1KDM4E | |
| SCHEMBL13664170 | 0.76 | MAPT (0.50) | MAPTKMT2AMEN1KDM4EMAPK1 | |
| SCHEMBL13664196 | 0.76 | MAPK14 (0.50) | MAPTKMT2AMEN1KDM4ENPSR1 | |
| SCHEMBL13664203 | 0.76 | MAPT (0.50) | MAPTKMT2AMEN1KDM4EMAPK1 | |
| SCHEMBL13664223 | 0.75 | MAPT (0.52) | CNR1MAPTKMT2AMEN1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090253673-A1 | Substituted Pyrazoles as Ghrelin Receptor Antagonists | MERCK SHARP & DOHME CORP. | 2009-10-08 | — | — | US | disclosed |
| US-20090253673-A1 | Substituted Pyrazoles as Ghrelin Receptor Antagonists | MERCK SHARP & DOHME CORP. | 2009-10-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090253673-A1 | Substituted Pyrazoles as Ghrelin Receptor Antagonists | GIPR, GPR119, GLP1R | CNR1 367/4885MAPT 4701/4885KMT2A 3722/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.